Prosthesis-patient mismatch is an independent predictor of congestive heart failure after transcatheter aortic valve replacement.


Journal

Archives of cardiovascular diseases
ISSN: 1875-2128
Titre abrégé: Arch Cardiovasc Dis
Pays: Netherlands
ID NLM: 101465655

Informations de publication

Date de publication:
Historique:
received: 28 04 2020
revised: 15 07 2020
accepted: 17 11 2020
pubmed: 30 1 2021
medline: 3 9 2021
entrez: 29 1 2021
Statut: ppublish

Résumé

Little is known about the effect of prosthesis-patient mismatch (PPM) on outcomes after transcatheter aortic valve replacement. We reported previously an increased risk of PPM with the SAPIEN 3 transcatheter heart valve (S3-THV). To investigate the association of PPM with 1-year outcomes in patients with severe aortic stenosis (AS) implanted with S3-THV. Moderate PPM was defined by an indexed effective orifice area (iEOA)≤0.85cm A total of 208 consecutive patients were included between 2016 and 2018. Male sex was prevalent (53.8%), mean age was 81.9±6.2 years, mean EuroSCORE II was 4.35±3.37, mean LVEF was 57.9±13%. Moderate and severe PPM were observed in 69 (33.2%) and 10 (4.8%) patients. Patients with PPM were younger (80.4±7 vs 82.8±5.41 years; P=0.006), had a larger BSA (1.84±0.19 vs 1.77±0.19 m PPM after S3-THV implantation is strongly associated with CHF at 1 year, but is not correlated with overall mortality.

Sections du résumé

BACKGROUND BACKGROUND
Little is known about the effect of prosthesis-patient mismatch (PPM) on outcomes after transcatheter aortic valve replacement. We reported previously an increased risk of PPM with the SAPIEN 3 transcatheter heart valve (S3-THV).
AIMS OBJECTIVE
To investigate the association of PPM with 1-year outcomes in patients with severe aortic stenosis (AS) implanted with S3-THV.
METHODS METHODS
Moderate PPM was defined by an indexed effective orifice area (iEOA)≤0.85cm
RESULTS RESULTS
A total of 208 consecutive patients were included between 2016 and 2018. Male sex was prevalent (53.8%), mean age was 81.9±6.2 years, mean EuroSCORE II was 4.35±3.37, mean LVEF was 57.9±13%. Moderate and severe PPM were observed in 69 (33.2%) and 10 (4.8%) patients. Patients with PPM were younger (80.4±7 vs 82.8±5.41 years; P=0.006), had a larger BSA (1.84±0.19 vs 1.77±0.19 m
CONCLUSIONS CONCLUSIONS
PPM after S3-THV implantation is strongly associated with CHF at 1 year, but is not correlated with overall mortality.

Identifiants

pubmed: 33509746
pii: S1875-2136(21)00003-6
doi: 10.1016/j.acvd.2020.11.005
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

504-514

Informations de copyright

Copyright © 2021 Elsevier Masson SAS. All rights reserved.

Auteurs

Alexis Theron (A)

Department of Cardiac Surgery, La Timone Hospital, 264, rue Saint-Pierre, 13005 Marseille, France. Electronic address: alexis.theron@ap-hm.fr.

Flora Lavagna (F)

Department of Cardiology, La Timone Hospital, 13005 Marseille, France.

Guillaume Gaubert (G)

EA 3279, Faculty of Medicine, 13385 Marseille, France.

Noemie Resseguier (N)

EA 3279, Faculty of Medicine, 13385 Marseille, France.

Alizée Porto (A)

Department of Cardiac Surgery, La Timone Hospital, 264, rue Saint-Pierre, 13005 Marseille, France.

Jerome Ferrara (J)

Department of Cardiology, La Timone Hospital, 13005 Marseille, France.

Nicolas Jaussaud (N)

Department of Cardiac Surgery, La Timone Hospital, 264, rue Saint-Pierre, 13005 Marseille, France.

Pierre Morera (P)

Department of Cardiac Surgery, La Timone Hospital, 264, rue Saint-Pierre, 13005 Marseille, France.

Thomas Cuisset (T)

Department of Cardiology, La Timone Hospital, 13005 Marseille, France.

Pierre Deharo (P)

Department of Cardiology, La Timone Hospital, 13005 Marseille, France; C2VN, Inserm, Inra, Aix-Marseille University, 13005 Marseille, France; Faculty of Medicine, Aix-Marseille University, 13385 Marseille, France.

Frederic Collart (F)

Department of Cardiac Surgery, La Timone Hospital, 264, rue Saint-Pierre, 13005 Marseille, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH